Russell Investments Group’s Mineralys Therapeutics MLYS Stock Holding History

Russell Investments Group’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.46M	Sell	128,247 -75,257	-37%	-$2.06M	﹤0.01%	1744
2026 Q1	$5.51M	Buy	203,504 +28,143	+16%	+$825K	0.01%	1290
2025 Q4	$6.36M	Buy	175,361 +172,097	+5,273%	+$6.9M	0.01%	1167
2025 Q3	$124K	Buy	3,264 +3,241	+14,091%	+$70.1K	﹤0.01%	2965
2025 Q2	$311	Buy	+23	New	+$333	﹤0.01%	3777
2024 Q2	–	Sell	-17	Closed	-$219	–	3609
2024 Q1	$219	Sell	17 -5,762	-100%	-$71.2K	﹤0.01%	3271
2023 Q4	$49.7K	Sell	5,779 -4,401	-43%	-$34.6K	﹤0.01%	2638
2023 Q3	$96.8K	Buy	+10,180	New	+$133K	﹤0.01%	2629

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Andera Partners Paris $206M AUM

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

TGY2IT

Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM

Russell Investments Group's MLYS Position: Q2 2026 in Review

Russell Investments Group reduced its Mineralys Therapeutics (MLYS) stake by 37% in Q2 2026, selling an estimated $2.06M and leaving 128,247 shares worth $3.46M. The position accounts for ﹤0.01% of the portfolio, ranked #1744.

Russell Investments Group first reported a position in MLYS in Q3 2023 and has held it in 8 quarters since. The position peaked at $6.36M in Q4 2025. 58 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

Russell Investments Group held 128,247 shares of Mineralys Therapeutics worth $3.46M as of Q2 2026.
Russell Investments Group sold 75,257 Mineralys Therapeutics shares in Q2 2026, an estimated $2.06M.
Mineralys Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #1744 holding.
Russell Investments Group first reported a position in Mineralys Therapeutics in Q3 2023 and has held it in 8 quarters since.
Russell Investments Group's Mineralys Therapeutics position peaked at $6.36M in Q4 2025.
58 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.